EP Patent

EP4112055A1 — Atropine-containing aqueous composition

Assigned to Santen Pharmaceutical Co Ltd · Expires 2023-01-04 · 3y expired

What this patent protects

Disclosed herein is an aqueous composition comprising 0.001 - 0.1 % (w/v) atropine or a salt thereof, and a phosphate buffer, which is at a pH range of 6 or lower.

USPTO Abstract

Disclosed herein is an aqueous composition comprising 0.001 - 0.1 % (w/v) atropine or a salt thereof, and a phosphate buffer, which is at a pH range of 6 or lower.

Drugs covered by this patent

oxymetazoline-hydrochloride (OXYMETAZOLINE HYDROCHLORIDE)

Patent Metadata

Patent number: EP4112055A1
Jurisdiction: EP
Classification: —
Expires: 2023-01-04
Drug substance claim: No
Drug product claim: No
Assignee: Santen Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.